B&BW ’08 goals
This article was originally published in The Rose Sheet
Bath & Body Works will focus on a few "key" priorities this year, including reinvigorating the brand, creating more brand consistency, and stemming current negative sales trend due to traffic decline in retail locations, B&BW CEO Diane Neal says during Limited Brands year-end (ended Feb. 2) earnings presentation Feb. 28. Company is focused on growing key brands C.O. Bigelow, True Blue Spa, aromatherapy and fragrant body care, she says. Limited Brands net sales for the year fell 5% to $10.13 bil. due to "transformational changes" that occurred through the year, while net income grew 6.2% to $718 mil. Limited Brands says disappointing results in 2007 "better position" the firm to prepare for core brand growth in 2008. In light of the retail environment, the number of projects planned for 2008 are reduced by 25%, with the goal of reducing planned capital expenditures of about $85 mil...
You may also be interested in...
Formycon’s CEO has offered the latest indication that the coronavirus outbreak could provide a tailwind for biosimilars, as the firm gave an update on its biosimilars pipeline – including ranibizumab, ustekinumab, aflibercept and an undisclosed molecule, as well as other unrevealed projects – and how it has been affected by the pandemic.
With the formal, virtual kick-off meeting set for 23 July, US FDA and sponsors are looking at a transformed landscape as they discuss what the next five years of user fees will look like.
Keeping Track: Approvals For Phexxi, Kynombi; New Claims For Lynparza, Alunbrig, Tecentriq; Intercept May Miss NASH User Fee Date
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.